Debu Tripathy, MD, discusses the TBCRC049 study investigating the use of tucatinib, capecitabine, and trastuzumab in the cerebral spinal fluid of patients with HER2-positive breast cancer and leptomeningeal disease.
Debu Tripathy, MD, professor and chairman of the Department of Breast Medical Oncology, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, discusses the TBCRC049 study (NCT03501979) investigating the use of tucatinib (Tukysa), capecitabine (Xeloda), and trastuzumab (Herceptin) in the cerebral spinal fluid (CSF) of patients with HER2-positive breast cancer and leptomeningeal disease (LMD).
This trial looked at the concentration of this combination in the patients’ blood and CSF. These data were reported at the 2021 American Society of Clinical Oncology (ASCO) annual meeting. The primary end points of response rate and time to progression will be reported in the future since the study is still ongoing. Tripathy says the poster presented at ASCO covered the CSF concentrations for patients on this trial, specifically.
The data showed that patients achieved concentrations that were in the range of 0.5 nm/mL, which is an active range in in vitro studies, according to Tripathy. This concentration was maintained over time. Numbers such as these have not been seen over time with many agents. The concentrations ranged from 0.2 to 4.7 nm/mL. The CSF to plasma ratio ranged from 0.18 to 4.0 in cycles 1 and 2, with a median of 0.87. He says these ranges did not appear to fluctuate much over time.
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More
Landgren on MRD as an End Point for Multiple Myeloma Trials
May 1st 2024C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Read More